Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Auteurs

H. S. Rugo, R. S. Finn, V. Diéras, J. Ettl, O. Lipatov, A. A. Joy, N. Harbeck, A. Castrellon, S. Iyer, D. R. Lu, A. Mori, E. R. Gauthier, C. Huang Bartlett, K. A. Gelmon, D. J. Slamon